Top advances of the year: Neoadjuvant immunotherapy in melanoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40305630.
- Also identified by DOI 10.1002/cncr.35877 and PMC identifier 12352971.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Overall, much progress was made in 2024 in the realm of neoadjuvant immunotherapy including the firm establishment of neoadjuvant immunotherapy as superior to only adjuvant immunotherapy for patients with resectable stage III melanoma with the NADINA trial results. However, unanswered questions remain regarding the optimal neoadjuvant immunotherapy regimen, long-term outcomes after modifying adjuvant approaches based on pathologic response, and if additional measurements of anti-tumor efficacy, in addition to pathologic response, can further help tailor adjuvant therapy decisions.